Stifel analyst Ben Burnett lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $118.00 (from $150.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE